The NeuroQuest teamWorld-class research paired with proven, top-line management provides the foundation for our organization
Chief Executive Officer
Mr. Touitou has served in a number of executive management positions guiding companies from development to commercialization of products in the pharmaceuticals, aesthetics, and OTC markets. He was former CEO of Juvenis Ltd. Israel, former founder and CEO of Novel Therapeutic Technologies (NTT). Dan earned an MBA with honors from Derby University, England and Bsc. Pharmacy with honors from the Hebrew University.
Dr. Gilboa brings more than a decade of business development experience, with particular expertise in life science. His former clients include Magnetecs Corp., the Haifa Life Science Park, and the Israeli Medical Association. Dr. Gilboa was the former CEO of R & D Supports Ltd., and vice president of business development and chief operating officer for Oshfir International Shipping and Custom Agencies. Etai earned his Ph.D. in political science from Haifa University.
Prof. Michal Schwartz
Founder, Chief Scientist
Professor Michal Schwartz is chair and vice president of the international society of Neuroscience, the Weizmann Institute in Israel. A world-renowned scientist, she serves on scientific advisory boards of global health organizations, is a frequent lecturer, presenter and has published extensively. Among Dr. Schwartz’s numerous awards the European Research Council (ERC) Award in 2008 as well as the 2015 Blumberg Outstanding Medical Research Scientist Prize. She holds a Ph.D. in chemical immunology and B.Sc. in chemistry from the Weizmann Institute.
Dr. Jacobo Mintzer
Vice President of Clinical Affairs
Dr. Mintzer is a professor of psychiatry, neurology, physiology, and neuroscience at the Medical University of South Carolina (MUSC) in Charleston, SC. He is chief of the Division of Geriatric Psychiatry and Fellowship programs at MUSC, and co-director of Alzheimer’s Research & Clinical Programs. Dr. Mintzer serves in numerous leadership roles of organizations furthering the treatment of Alzheimer’s and age-related diseases.